PDA: A Global. Association. Contamination Control: Particles, Bio-contamination, Aseptic manufacturing. PDA Parenteral 2014 Munich Conference
|
|
- Jasmine Small
- 6 years ago
- Views:
Transcription
1 PDA Parenteral 2014 Munich Conference PDA: A Global Contamination Control: Particles, Bio-contamination, Bioburden Association and Endotoxins in Aseptic manufacturing. James Drinkwater F Ziel Head of Aseptic processing technologies & GMP Compliance. Chairman of PHSS.
2 Contents Contamination Control & Cross Contamination Control. What s new in Industry, Pharmacy requirements < WHATS NEW > In knowledge In GMP What s new in regulatory expectations and initiatives Contamination Control: Particles, Bio-contamination, Endotoxins: Strategies, Principles, Disinfection, Techniques, Procedures. Environmental monitoring, Bioburden, Sterility, Endotoxin testing Through phases of establishing control to formal state of control Initiatives: following on from QMS, QbD, QRM, PAT, CPV and Q-Metrics the EU GMP Annex 1 is in process for revision. Under review for Annex 1 are Control Strategies for manufacturing Sterile Drug products/ substances. Best Practice Guidance: The PHSS have published a Bio-contamination Life cycle Technical monograph reviewed by the MHRA before publication. The PDA are preparing a Technical Report on Cleaning and Disinfection. 2
3 What s New: Knowledge Photographs courtesy of F Ziel GmbH. Gowned operators generate microorganisms so following Quality by Design principles a physical separation barrier between the process/ product and the most contaminating source people e.g. with Isolators, RABS is required particularly in Aseptic processing that is increasing with new biological products. Environmental monitoring is limited in recovery with limited sample sizes and sample areas/ volumes meaning we only have an indication not absolute values on contamination levels; trends (much data) are needed to indicate state of control. A single measuring event has little value on its own. We are still learning about disinfection and developing new approaches: Manual, Semi-automatic and Automatic. Isolators are typically decontaminated with vh 2 O 2 VHP (bench mark), other automated gaseous disinfection processes may apply, and still there is not widespread knowledge in this area: An understanding of Science, Process and Microbiology are key to efficacy, efficiency and GMP compliance. Despite being an established process the industry still has problems with Moist heat sterilisation 3
4 Challenges of Resident and Transient micro-flora in Controlled Environments Microflora on Hand transfer Microflora on Materials in transfer Microflora transfer from Surrounding Environment Controlled Environment Controlled Zones 4
5 Containment & Cross Contamination control Pharmaceutical Containment Hierarchy Biological safety rooms and cabinets: Biological safety Levels Rooms BL1,2,3,4 & Class 1,2,3 cabinets Containment of Biologically hazardous, toxic, pathogenic organisms, products/substances for operator protection. Requirements detailed in Biosafety standards. AP1 Active Pharmaceutical Ingredient containment: API Powder containment including non sterile products Containment levels referenced in API micro-grams by cubic metre for operator protection. Powder containment in Isolators (turbulent flow) and closed systems. Aseptic and Toxic containment in Aseptic processing of sterile medicines, drugs and drug substances. Using Isolator technology with Safe Change Filter barrier containment and CIP / decontamination features Product and operator protection to O.E.L. including containment for cross contamination control 4 Aseptic and non pathogenic biological product containment in Aseptic processing of sterile medicines, drugs and drug substances. Product protection and containment for cross contamination control using Isolator barriers. 5 Aseptic processing with product protection Product protection using Barrier Separation Technology (Isolators and RABS). 5
6 Classified Area Zonation Unclassified RABS Areas / zones EU Grade D : at Rest ISO8: In Operation EU Grade C in operation EU Grade B in operation ISO8 in operation ISO7 in operation Cleanrooms Aseptic core EU Grade A ISO 5 in operation Isolators EU Grade C at Rest BFS ISO7 in operation Air Flow and Pressure Cascade 6
7 Control Targets: Total particulate & Microbiological levels GMP Annex 1 > ISO Parts 1 & 2 Total Particles Viable & Non viable > Personal & Material Transfers 3 log (0.5 µ ) (5 µ) at Rest. EU : D n/a 200 cfu (0.5 µ ) (5 µ) <In Operation> C : ISO log n/a 3log 100 cfu (0.5 µ ) 2900 (5 µ) B : ISO cfu 3/6 log 3520 (0.5 micron) 20 (5 micron) A ISO5 <1cfu = 0 cfu Controlled Direct input Utilities / services e.g. WFI & HVAC Microbiological Contamination as colony forming units > (cfu) Settle plates max cfu. Contact plates max cfu. Glove prints max cfu. Active air cfu / cubic metre. <In Operation> ISO FDA guidance. USP<797> & <1116> Air flow & Pressure Cascade direction 7
8 What s New in Contamination Control :Barrier Separation Technology A-ISO5 B ISO7 RABS Do we really understand what the differences are between Isolators and RABS with all the configuration variants and what is best for a given application. Do we understand the Contamination control attributes of Barrier Separation Technology and how they are applied for contamination control. Do we understand how containment applies for Pharmaceutical applications, other than APIs; powder particle containment that are well characterized. Could we finally be making progress with implementation with RMM/ RTM? 8
9 Open & Closed Design RABS Open & Closed Operation RABS RABS: Combination or Physical and Aerodynamic barrier. Passive or Active Air management Open Design RABS Active Air management +ve Closed Design RABS A-ISO5 SIP- AIP GIP* B ISO7 Transfer port closed after use Open & Closed Operation Using Open or Closed Design RABS. Open barrier door operator interventions are risk assessed, justified, controlled and monitored. Airflow protection at open door. Open Operation RABS A-ISO5 Best practice: Closed Operation RABS After set up and last Bio-decontamination step barrier doors remain closed for complete aseptic processing operation. Interventions only by barrier gloves for SIP- AIP or GIP Air over spill limited to *VHP-GIP transfer ports possible. operators & controlled 9 access ports for materials. SIP=Sterilise in place. AIP= Aseptic/assembly-GIP=Gassing in Place.
10 Hierarchy of Biological Reduction Biological Reduction Hierarchy 1 2 Sterilisation: Moist Heat, Dry Heat Gamma irradiation, ETO Penetrative processes fully referenced in pharmacopeia's delivering a defined sterility assurance level (SAL) Automated Surface Sterilisation Non-chemical based automated surface sterilisation Chemical based automated Gaseous Surface Sterilisation in combination with residue free cleaning to prevent chemical contamination transfer to products 3 Automated Gaseous Disinfection (airborne and surfaces) examples include Hydrogen peroxide vapour vh 2 O 2 / VHP 4 Semi-automated aerosol/ fogger disinfection (airborne and surfaces) examples include Dry fog, nebulisers 5 Surface Manual Disinfection Processes; In-process efficacy qualification Surface Manual Disinfection Procedures: Laboratory qualified efficacy. in-process qualification of agent application via procedures (SOPs). EM used to monitor impact on microbial control 10
11 Holistic Decision making Separation Barrier Technology selection Regulation Operations Separation Barrier Technology selection Product Process Facility Use a control strategy to consider each area for key requirements / issues that influence the Barrier Technology: Isolator or RABS selection. 11
12 Contamination Control 12
13 PHSS Bio-contamination Monograph Structure Chapters 1 Chapters 2 Chapters 3 Chapters 4 Bio-contamination Characterisation & profiling Biocontamination Control of classified areas Environmental monitoring of airborne & Surfaces Biocontamination Deviation management EM Sample plans 13
14 Control Strategies Sterile Products Manufacturing: PHSS White Paper 14
15 Control Strategies A Control Strategy should be considered to include: All are inextricably linked. Manufacturing control strategy; based on product type, demand, process and risk. Quality control strategy; based on understanding of risk with control of Critical Quality Attributes (CQAs) in a manufacturing process meeting regulatory requirements. Contamination control strategy including cross contamination control that may include requirements for containment/ product segregation. A PHSS white paper on Control Strategy for Manufacture of Sterile Products has been released. 15
16 Characteristics of a Control Strategy Key characteristics of a control strategy for contamination control would be considered as: Product and process knowledge and skills in pharmaceutical product manufacturing and GMP/ cgmp compliance critical to an effective risk based approach to control. Under the auspices of a Pharmaceutical Quality System (PQS) together with initiatives of Quality by Design (QbD) and Quality Risk Management (QRM). All changes as a result of increasing knowledge, process improvements are subject to a change control process. Dynamic and iterative throughout the product life cycle. Holistic and proactive. Based on targeted/ risk based measures of contamination avoidance Uses key performance indicators (KPIs) to assess status of contamination control Includes a defined strategy for deviation management: investigations and CAPA. 16
17 Contamination Control in Isolator Barriers: Aseptic Containment Filling Personnel Gowning monitoring Clean/ Sterilize Vials Sterile Vial In feed Concept courtesy of F Ziel Rapid Decon VHP EM plates & parts Photo: Courtesy of Pharmagraph Biological Product Filling Track & Trace Bar-coded EM Plates Finished Product Sterile Caps & Stoppers Active mouse hole with Filter barrier Cap 1. Buffer Cap 2. Lyo Interface 1. Lyo Interface 2. Lyo 1 Lyo 2 17
18 Isolator/ RABS Leak Integrity Classes 18
19 Isolator Glove Leak integrity Testing: in-situ Wireless Glove Testing now best practice. Limit of detection improving from 100 to 70 micron with new developments. Many gloves tested in same time frame: 15 minutes. Test Ports use inflatable seal technology to avoid false failures. Pressurising pumps are fully integrated and battery operated (with separate charging station). RFID tags on Glove test port and Isolator Glove port record position and Glove in test. Compliant electronic data capture and reporting. Glove hole impact research in progress: microbiological challenge testing. W-LAN Glove Testing Systems 19
20 RABS Filling of Clinical trial batches of virus based product in Vials Change rooms + pa ++ pa Pre-packaged Sterile parts vh 2 O 2 + Airclean Grade B ISO 7 Cleanroom + vh 2 O 2 decontamination ++ Pa: Pressure regime Open Design RABS Closed Operation RABS + inherent & corrective interventions. Pre-sterilised Containers > De-bag 1. De-bag 2 > Filling & Stoppering UDF airflow protection at Air-overspill access interfaces +++ pa ++++ pa +++ pa +++ pa Capping Filled product Exit buffer Pre-sterilised containers: Air-clean / alcohol disinfection transfer Sterilised parts: Stopper bowl Caps bowl Track-ways Barrier Gloves Waste on exit Single use systems (Product bag, lines) Air-clean / alcohol disinfection transfer EM plates in VHP barrier packaging - vh 2 O 2 decontamination transfer Exit decontamination of outside of filled vials (virus clearance less than 30C) Product from formulation Autoclave 20
21 Manual Cleaning & Disinfection 21
22 Manual Disinfection of classified and controlled areas There is no consensus on definition of the terms disinfection and sanitisation. Qualification of manual disinfection/ sanitisation processes that have an in-process efficacy challenge or procedures that use laboratory qualified agents and qualified procedures of application with EM used to monitor impact on contamination control. Qualification of disinfectant: Standard European approach Standard U.S. approach A PHSS recommended practice for laboratory testing of a disinfectant for use in manual disinfection is included in the Bio-contamination monograph The approach is based on an adaption of standard (generic) approaches for specific use in pharmaceutical and hospital GMP/ cgmp Classified and controlled areas. A new PDA Cleaning and Disinfection TR is in final stages of review. 22
23 Semi automated aerosol (fogger) disinfection technology Semi-automated disinfectant aerosol systems termed as Foggers, Dry foggers, atomisers, have a role in cleanroom and controlled area disinfection to improve the distribution, uniformity in application of disinfection agents for large volumes / surfaces over that of the manual application of agents. There are process, efficacy and compatibilities challenges to consider in selection. 23
24 Automated Gaseous Disinfection Automated Gaseous Disinfection, under validated conditions, provides repeatable and robust biological decontamination of controlled areas/ zones; airborne and surfaces at relatively low temperature conditions, typically below 30 degrees Celsius. It should be noted that Gaseous disinfection is a finishing step and areas also require pre-cleaning to remove soiling layers that would protect microorganisms from the surface disinfection process. Also only surfaces that are exposed to the gaseous disinfection agent will be disinfected. The Gaseous disinfection agents may vary but there is a more limited choice when considering issues of material compatibility, requirements for a residue free process together with operator/ personnel and environmental safety. 24
25 Single Use Systems (SUS) used in Barriers Consider disinfectant compatibilities, particularly oxidising agent (VHP) compatibility with biological products e.g. ingress through packaging during transfer into an aseptic manufacturing environment. Consider the challenge of transfer into pre-gassed Isolator RABS without microbiological compromise of the classified environment. Validate bio-compatibility with Disinfection process - manual or Gaseous and product or validate avoidance of contact/ peameation.. Photograph courtesy of Millipore Bioprocess division Consider maintaining sterile integrity of SUS through the supply chain to point of use, including manipulation in set up after sterile outer packing is opened. 25
26 Hydrogen peroxide Vapour (VHP) Automated Gaseous Disinfection selection Key considerations in selecting Automated Gaseous Disinfection for the Barrier System (Isolators or Closed Design RABS) H 2 O 2 / VHP disinfection optimised by: Rapid kill with targeted H 2 O 2 molecule delivery mechanisms. Rapid Aeration without over saturation minimum dosage. Managing the VHP condensable vapour in process design is critical to VHP cycle performance and optimum (short) cycle times Surface Sterilization: (GIP) Gassing-in-place requires special considerations in cleaning validation to prevent chemical contamination of products Biological products can be impacted by VHP residuals so cycle end points become critical HRP analysis can be used in studies for bio-compatibility Target is for as short as possible production down time and optimum turnaround through cleaning and disinfection stages 26
27 VHP cycle end points for Biological products Case study results; VHP graphical presentation of concentration reduction over time. AerationH 2 O 2 Time Time [ppm] Sensor 11:45 00:50 1.4ATI 12:00 01:05 1.1ATI 12:15 01:20 0.9ATI 12:30 01:35 0.8ATI 12:45 01:50 0.7ATI 13:00 02:05 0.6ATI 13:15 02:20 0.6Dräger 13:30 02:35 0.5Dräger 13:45 02:50 0.5Dräger (+) 14:00 03:05 0.5Dräger (-) 14:15 03:20 0.4Dräger 14:30 03:35 0.3Dräger By Design of Barrier critical to cycle time: Total VHP cycle time to 1ppm 2hours 12 minutes to 0.3 ppm 4hours 30 minutes >>>> 0.03ppm 0.3ppm H2O2 [ppm] H 2 O 2 ppm :50 01:05 01:20 01:35 01:50 02:05 02:20 02:35 02:50 03:05 03:20 03:35 H2O2 Gas and solution residuals at ppb levels 27
28 Monitoring the performance and deviation in Contamination Control 28
29 Risk based Sample Locations Value of sampling location? HEPA filter delivering First Air Air disturbance potential contaminating source. I M 3 Columns of First clean air Point of Fill Settle Plate 29
30 Holistic monitoring of the microbiological profile to detect and respond to escalation in bio-contamination transfer risk to Grade A. Move from reactive to proactive Bio-contamination risk management Grade A Contamination event: RCA. CAPA. Batch loss? Grade B Grade C Surface Settle Plate Active Air Current Microbial Standards Holistic monitoring of profile recognise the relationship between zones 30
31 Microflora groups The microbiological monitoring microflora profile groups defined in the PHSS Bio-contamination Monograph are: Bacilli Gram negative rods: related to endotoxin risks. Human commensals Moulds and yeasts Others; including environmental non-sporing rods Defined; atypical microorganisms. Gram Negative microorganisms would be considered objectionable in environments close to where products are manufactured/ exposed. 31
32 Bio-contamination Risk Profile table EU Grade D EU Grade C EU Grade B EU Grade A Cfu levels Reference Actuals (range). Bio-contamination Risk profiling table Cfu levels Cfu levels Cfu levels % incidence of deviation. % incidence of deviation. % incidence of deviation. % incidence of deviation. Flora profile Flora profile Flora profile Flora profile 1. Reference 2. Harmful & objectionable. 3. Trends groups. 1. Reference 2. Harmful & objectionable. 3. Trends groups 1. Reference 2. There would be an expectation not to detect any spores or moulds/ fungi in Grade B areas. There should be no detectable microorganisms in Grade A hence all are objectionable. 32
33 Microflora characterisation through establishing control to formal state of control The relative percentage change of one microbiological group to another will shift inherently through transition of establishing control into a control state. Thereafter there may be seasonal changes or as a result of other influences, possibly changes related to external facility activities. Once typically found micro-flora is understood in the control state, then deviation from the characterised and expected flora; by cfu levels, by incidence rates, by micro-flora group type, can be defined as a risk escalation to contaminating Grade A facilitating a proactive response. 33
34 Presenting data: Micro-flora Pie chart profiles 34
35 Risk Profiling and Proactive Response - RPPR Increased risk to Grade A by Bio-contamination transmission through D>C>B to A Risk profiling cfu levels - holistic Microbiological flora D > C > B > A Holistic Monitoring D > C* > B > A Proactive response to profile change & increased risk to A C* = Increase bio-contamination control and monitoring in Grade C. Profile the measurable cfu s in Grade C to detect increased risk to Grade A. CAPA Corrective & Preventative Action Investigate root cause to change in microbiological profile Less emphasis on Grade A where zero cfu is expected and deviations are reactive possibly with loss of batch 35
36 Challenges of characterising a microbiological profile as typical flora in Grade C areas Challenges in monitoring in Grade C areas will include the following: There will need to be an increase in environmental monitoring (EM) resource. Focus where the greatest challenges are. Grade C areas are not aseptically controlled in the same way as Grade A or B so there is more variation of flora. Water may be present. By necessity, equipment operates that is not fully enclosed or sterilised. Non-sterile materials are handled. A higher number of operators are present compared to Grade B rooms. Given the above, the micro-flora is continuously changing in numbers and species. Determining typical flora could be difficult, but once established then the holistic profile and deviation from the characterised expected profile in microbiological flora becomes a key performance indicator (KPI). 36
37 Benefits of RPPR initiative Reduces the bio-contamination risk to both patients and sterile products Detection of a changing environmental profile and taking appropriate controlling or intervening action to re-establish control before the Grade A/ISO5 barrier is compromised or beached improves contamination control performance and risk management. RPPR profiles are a Leading KPIs Key performance indicators relating to bio-contamination control. Reduces costly and largely inconclusive root cause investigations. Improves regulatory compliance. Gain more knowledge about the changing environment in the Grade C/ISO8 zones and understanding of how to better control it. Reduces risk of batch loss due to non-compliance in bio-contamination monitoring results and potentially sterility. 37
38 SUMMARY Contamination Control Aseptic processing Drives the need for Separative Barriers Operations: Closed Operation is best practice. Human factors play a role We have greater knowledge but increasing challenges Product types have a significant impact on Control Strategy Disinfection/ Sterilisation regimes and interactions have a significant impact Facility design forms part of contamination control with barriers EU GMP annex 1 is changing to reflect new knowledge, changing product profiles. Increasing complexity drives the need for Control Strategies. 38
On behalf of the PHSS Pharmaceutical and Healthcare Sciences Society (UK).
31 st March 2015 Submission of comments on ' Concept paper on the revision of annex 1 of the guidelines on good manufacturing practice manufacture of sterile medicinal products EMA/INS/GMP/735037/2014
More informationOverview and Introduction Annex 1 Revision
Overview and Introduction Annex 1 Revision Paul Moody, Inspector Pharmig Current Hot Topics in Pharmaceutical Microbiology, Dublin May 30 th, 2018 Scope History Process of Revision Rationale for Revision
More informationBiological contamination events in isolators: What lessons can be learned?
WHITE PAPER SCIENCE DRIVEN BIO-DECONTAMINATION LS001-MKT-008 Rev 1US Biological contamination events in isolators: What lessons can be learned? James Drinkwater, Bioquell UK Process & Compliance Director.
More informationBio-contamination control PHSS Technical Monograph No. 20. Gordon Farquharson, July 2016
Bio-contamination control PHSS Technical Monograph No. 20 Gordon Farquharson, July 2016 The UK PHSS (Pahramaceuical and Health Care Sciences Socierty prepared Monograph No. 20 in September 2014. This presentation
More informationGetting it Right Microbial Quality Risk Management
Programme Linda Musker Quality Control North West Mark Oldcorne All Wales Pharmaceutical Quality Assurance Getting it Right Microbial Quality Risk Management Strategic Background (MAO) The Problem (LM)
More informationWebinar. The New EU-GMP Annex 1 draft Dupont. GOP-Innovations your Partner for Practical Training and e-learning. 8 June 2018
Webinar The New EU-GMP Annex 1 draft Dupont 8 June 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, consultant, trainer, coach 10 years
More informationHow to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant
How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant Randy Hutt, Ph.D. Associate Director Sterility Assurance and Microbiology Luitpold
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationBiocontamination control in pharmaceutical production
White Paper Data Sheet Biocontamination control in pharmaceutical production and compliance to ISO 14698 with validated active microbial air samplers Tim Sandle, Ph.D., Head of Microbiology at Bio Products
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationFZ LABORATORY SERVICES
FZ LABORATORY SERVICES For those working in biological product manufacturing/aseptic process filling: you can greatly benefit from support by Franz Ziel GmbH (FZ) with many years experience in scientific
More informationPreparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014
Preparing Your Aseptic Processing Facility for an FDA Inspection Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Agenda Regulatory Requirements Establishing your Approach Aseptic Controls
More informationMicrobiology. 3 How to deal with non-sterile results in aseptic processing
Microbiology 3 How to deal with non-sterile results in aseptic processing Dr. Guenther Gapp, Gapp Quality GmbH 8 Risk Profiling and Proactive Response (RPPR) to Bio-contamination in GMP classified and
More informationEnvironmental Control Requirements. Gordon Farquharson July 2017
Environmental Control Requirements Gordon Farquharson July 2017 Learning Objectives Learn how contamination control standards and guidance sets requirements for Critical Parameters ISO-14644-1 Classification
More informationEnvironmental Monitoring of Aseptic Processing Areas - 2
Environmental Monitoring of Aseptic Processing Areas - 2 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Active Air Monitoring (Viables) Air Sieve Samplers Draw air
More informationEnvironmental Monitoring of Aseptic Processing Areas - 1
Environmental Monitoring of Aseptic Processing Areas - 1 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Training Course Agenda Overview of Environmental Monitoring
More informationIsolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite
APV 2008 Basle Conference Basle, Switzerland: May 28 & 29 2008 Isolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite John R. Chester Principal Engineer Global Pharmaceutical
More informationMicrobiological Consideration for Non-Sterile Pharmaceutical
May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control
More informationMicrobiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A
USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity
More informationCONTAINED ASEPTIC TRANSFER VALVES
CONTAINED ASEPTIC TRANSFER VALVES Applications Contained filling and dispensing for all production processes. aseptic transfer valves can be integrated into the production of both powder and liquid formulations
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. This document is for consultation until 11 December 2015
Ref. Ares(2015)3808922-15/09/2015 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Medicinal Products Quality, Safety and Efficacy Brussels, [date] This document is for consultation until 11
More informationANNEX 1: COMMENT SUBMISSION DOCUMENT
Submission Comments on: GMP Annex 1: Proposal for amendments to the environmental classification table for particles and associated text, amendment to section 42 concerning acceptance criteria for media
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationCompounding Aseptic Isolators (CAI) James T Wagner
Compounding Aseptic Isolators (CAI) James T Wagner jimwagner@cenvironment.com Disclaimer "Although I am a member of the USP Sterile Compounding Expert Committee, I am speaking today in my individual capacity
More informationEU GMP ANNEX 1 CHANGES CLARIFICATION AND IMPACT
1 EU GMP ANNEX 1 CHANGES CLARIFICATION AND IMPACT UNDERSTAND THE PROGRESSION OF REGULATORY THINKING AND HOW TO SUCCESSFULLY IMPLEMENT THE PROPOSED CHANGES BALTIMORE, MD MAY 6TH AND 7TH, 2019 UNIVERSITY
More informationBest Practice in Environmental Monitoring
Best Practice in Environmental Monitoring Annette Grundy July 12 2016 1 Acknowledgement Dr Ed Tidswell previous roles at Baxter Senior Director R&D and Quality Director USP expert committee member Ed was
More informationCONTAINED ASEPTIC TRANSFER VALVES
1 CONTAINED ASEPTIC TRANSFER VALVES Perform aseptic transfers that maintain critical area integrity. Reduce risk of cross contamination with closed transfers that limit manual intervention. Meet GMP and
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationSchool of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April McGee Pharma International
School of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April 1 Parallel Session - Sterile Facilitator Ms Ann McGee 2 Query Topics Contamination Control Strategy Problems virtually managing
More informationINSPECTOR S OBSERVATIONS AND WARNING LETTER
Microrite, Inc. San Jose, CA, USA, http://www.microrite.com AIR VELOCITY MEASUREMENTS AND CORRELATION TO SMOKE STUDIES FOR ASEPTIC OPERATIONS KEYWORDS Air Velocity, Air Flows, Smoke Study, Air Pattern
More informationWhy change is inevitable in aseptic manufacturing?
Why change is inevitable in aseptic manufacturing? Chrissie Fuchs, Marketing & Communication at Fedegari Group Sergio Mauri, Manager, Integrated Projects at Fedegari Group Key words: Aseptic manufacturing
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationAdvancements on implementation of single use technology in vaccine manufacturing
Advancements on implementation of single use technology in vaccine manufacturing October 25 th, 2013 DCVMN Meeting Rio de Janeiro, Brazil Outline Overview of single use products Applications of single
More informationMedia Fill A Process Simution. Presented By Shikha Chauhan
Media Fill A Process Simution Presented By Shikha Chauhan 21 CFR 211.113 Validation of Aseptic Processing and Sterilization Process Simulation / Media Fill Filtration Efficacy Sterilization of Equipment,
More informationOverview of Inspection Issues with Legacy Products. Barbara Breithaupt Consumer Safety Officer
Overview of Inspection Issues with Legacy Products Barbara Breithaupt Consumer Safety Officer 1 Overview of the presentation The role of the Quality Unit will be discussed in the context of the inspection
More informationQuality Risk Management
Quality Risk Management Audit Expectations and Observations Matthew Davis Lead Auditor Office of Manufacturing Quality, TGA CAPSIG 4 th May 2011 www.tga.gov.au 2 QRM - TGA Expectations and Observations
More informationContainment Why and How to evaluate
Containment Why and How to evaluate IDMA- APA PAC 2018 May 18 & 19 At The Club, Andheri - Mumbai Presentation by: Sasidharan S Menon Subject Matter Expert (SME) Design and Evaluation Controlled environments
More informationAvoid recurrent microbial contamination using trending of historical data. El Azab Walid Technical Service Manager STERIS
Avoid recurrent microbial contamination using trending of historical data El Azab Walid Technical Service Manager STERIS Agenda Factors influencing the cleaning and disinfection performance Recurring microbial
More informationLUNCH AND LEARN. September 11, CE Activity Information & Accreditation
LUNCH AND LEARN Environmental Monitoring and Contamination Control September 11, 2015 Featured Speaker: Scott Sutton, Ph.D. The Microbiology Network N. Chili, New York 1 CE Activity Information & Accreditation
More informationPharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD
Pharmaceutical Compounding Sterile and Nonsterile Preparations Jeanne Sun, PharmD Agenda Legal Framework Overview Pharmaceutical Compounding Nonsterile Preparations Pharmaceutical Compounding
More informationCurrent Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)
Current Trends in Sterile Manufacturing by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS) Executive Summary Drug developers go to great lengths to assure that their
More informationPhEn-602 Notes # 4 J. Manfredi
PhEn-602 Notes # 4 J. Manfredi Spring 2009 1 Basic definitions Clean Room: A room in which the concentration of airborne particles is controlled and contains one or more clean zones Clean Zone: A defined
More informationRecent USP Updates May, 2013
Recent USP Updates May, 2013 Don Singer GSK Bioburden Control of Non-sterile Drug Substances and Products The chapter emphasizes control as a risk mitigation strategy The chapter recommends a risk-based
More informationAseptic Processing Practices and Process Validation of Aseptic Operators
Aseptic Processing Practices and Process Validation of Aseptic Operators CBE Pty Ltd This training program is copyright to CBE Pty Ltd and may not be modified, reproduced, sold, loaned, hired or traded
More informationMINIMUM REQUIREMENTS FOR A VENDOR
MINIMUM REQUIREMENTS FOR A VENDOR When outsourcing the production of sterile products the first step in vendor evaluation is to see if they meet the minimum requirements. We ve developed a group of questions
More informationGuiding Principles for the implementation of fluid management technologies for modern single use aseptic processing
Guiding Principles for the implementation of fluid management technologies for modern single use aseptic processing Jean-Marc Cappia, Vice President Marketing Fluid Management Technologies Agenda 1. Aseptic
More informationQ&A summary report from PHSS Annual conference 2015; EU GMP Annex 1 revision discussion panel.
Q&A summary report from PHSS Annual conference 2015; EU GMP Annex 1 revision discussion panel. PHSS panel Discussion on questions set relating to revision of EU guidance to Good Manufacturing Practice
More informationOverview of Inspection Issues with Legacy Products
Overview of Inspection Issues with Legacy Products Presented by Simone E. Pitts Consumer Safety Officer, USFDA Team Biologics simone.pitts@fda.hhs.gov Objective To provide some examples of recent inspectional
More informationSterilization - validation, qualification requirements. Sterilization - Overview
Sterilization - validation, qualification requirements Dawn Tavalsky 1 ISPE Boston Chapter Framingham MA 19Sep2013 Sterilization - Overview Objectives Discuss definition of Sterile Briefly describe sterilization
More informationBioburden Contamination Control: A Holistic Overview
Bioburden Contamination Control: A Holistic Overview Scott Sutton, PhD Microbiology Network, Inc. Scott Sutton, PhD is the Principal of Microbiology Network, Inc (http:// microbiologynetwork.com/) a company
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationEU Guidance / Q&A. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin
EU Guidance / Q&A Greg McGurk, GMP Manager (acting) GMP Conference 7 February 2017 Dublin TPN Manufacture Q&A TPN Guidance Proposed at IWG that working group be formed to draft guidance Several adverse
More informationGuidance for Industry
Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center
More informationNHS QA Symposium, September 2013
1 www.pmtgb.com Germany - Benelux T o g e t h e r W e c r e a t e S o l u t i o n s France - Great Britain NHS QA Symposium, September 2013 John Cobb Microbiology Support Manager 2 www.pmtgb.com Germany
More informationTesto Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance
Testo Expert Knowledge The GxP Dictionary 1st edition Definitions relating to GxP and Quality Assurance Note: Some of the information contained in this GxP Dictionary does not apply equally to all countries.
More informationGUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES
GUIDE TO INSPECTIONS OF MICROBIOLOGICAL PHARMACEUTICAL QUALITY CONTROL LABORATORIES Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA,
More informationHVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction
HVAC and Risk Management RACI Meeting 7 th December 2011 Dr Stephen Firmer Asia Pacific Consultants Pty Ltd Agenda Context Project Management Design Construction Qualification Routine Control /Potential
More informationQuality by Design in Critical Filtration Operations
Quality by Design in Critical Filtration Operations Michael Payne Senior Biosafety Technical Consultant Yanglin Mok Technical Manager Objectives Define quality by design (QbD) and Quality Risk Management
More informationInspection Hot Topics
Inspection Hot Topics QP Forum, Trinity College Ciara Turley, Inspector, HPRA 16 th April 2015 Content Hot topics = common deficiencies Data based on 100 inspections conducted in 2014 Inspections of non-sterile
More informationPDA: A Global Association
Achieving Meticulous Aseptic Standards & Control in a Filling Isolator PDA: A Global Association Lessons for Design Aidan Harrington PhD Senior Consultant DPS Engineering, Cork Ireland Preface Agalloco,
More informationISPE Nordic, Denmark Yves Scholler SKAN AG
Risk of contamination through pinholes in gloves and how to prove the integrity ISPE Nordic, Denmark Yves Scholler SKAN AG 07.10.2015 1 Agenda 1 Regulatory Requirements 2 Overview of Different Testing
More informationPDA: A Global Association. Simone Bläsi
PDA: A Global Association Simone Bläsi How it all began the field of clean room equipment and construction of isolators for the pharmaceutical chemical industry Depending on customer request, you are responsible
More informationContamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC
Contamination Risk Assessment in Aseptic, Non-Sterile and Terminally Sterilized Products March 7 th & 8 th Raleigh, NC Contamination risk levels differ in aseptic, and non-sterile and terminally sterilized
More informationGloveless Robotic Technologies in Aseptic. Personalized Cytotoxic. Association. Drugs. Sergio Mauri FEDEGARI GROUP
Gloveless Robotic Technologies in Aseptic PDA: Manufacturing A Global for Personalized Cytotoxic Association Sergio Mauri FEDEGARI GROUP Drugs Presentation outline Pharma outlook trends and the aseptic
More informationFlexAct BT (Bag Tester) Flexboy 2D November, 2015
FlexAct BT (Bag Tester) Flexboy 2D November, 2015 Agenda 1 2 3 4 Container Closure Integrity for SUS FlexAct BT Value Proposition FlexAct BT Instruments FlexAct BT SU Flexboy 2D 5 FlexAct BT Validation
More informationSupplementary Training Modules on Good Manufacturing Practice. Validation. WHO Technical Report Series, No. 937, Annex 4.
Supplementary Training Modules on Good Manufacturing Practice Validation WHO Technical Report Series, No. 937, 2006. Annex 4. Validation Slide 1 of 48 August 2006 Validation! Part 1. General overview on
More informationCONTENTS About the Authors xiii 1 ENVIRONMENTAL MONITORING 1 Jeanne Moldenhauer Overview 1 Components of an Environmental Control System 2 Facility Design and Maintenance 3 Documentation Systems and Procedural
More informationAseptic Processing Current Issues & Trends
Aseptic Processing Current Issues & Trends 1 Introduction Richard M. Johnson Member, PDA for 20+ years President & CEO since 2009 Ladies and Gentlemen, I am happy to be here with you. Senhoras e Senhores,
More informationMicrobiological Cleaning Method Validation
Microbiological Cleaning Method Validation The purpose of cleaning procedures should never be to reduce bioburden to an acceptable level! Fergus O Connell QA Manager Eurofins ams Laboratories www.eurofins.com
More informationThe Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager
The Application of Pharmaceutical cgmp to Live Bacterial Products James Harris Business Development Manager The Objective CMC expectations of a cgmp live bacterial biopharmaceutical project Overview Define
More informationAdvances in Sterility Assurance: Single Use Devices and Rapid Microbiological Tests
Without measurement there is no control Abstract The last decade brought an impressive list of technological advances, ensuring the sterility and quality of a myriad of new drug and biological products,
More informationGUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS
GUIDE TO INSPECTIONS OF STERILE DRUG SUBSTANCE MANUFACTURERS Note: This document is reference material for investigators and other FDA personnel. The document does not bind FDA, and does no confer any
More informationCritical Environment Products and Services
Critical Environment Products and Services For over two decades, EP Scientific products and services have defined clean for environmental sampling containers and services. Our proprietary cleaning methods
More informationWhy Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services
Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and
More informationValidation Needs for Sterilization by Aseptic Filtration
Validation Needs for Sterilization by Aseptic Filtration DCVMN Workshop, Hyderabad, 4-8 April 2016 Ramesh Raju Associate Director - Provantage Validation Services Overview Key Regulatory and Industry guidelines
More informationIs it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS
Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS Agenda Annex 1 revision why? Impact of the change on the field Conclusion The Revision
More informationImplementation of Enhanced Active Air Particle Counting. Jeffrey W. Weber Kalamazoo, MI May 5, 2015 PDA Midwest
Implementation of Enhanced Active Air Particle Counting Jeffrey W. Weber Kalamazoo, MI May 5, 2015 PDA Midwest Agenda Introduction Regulatory Aspects Case Study: Investigation Future Role: Elimination
More informationInnovative H 2 O 2 V-Phase biodecontamination solutions
Innovative H 2 O 2 V-Phase biodecontamination solutions ENEMY ZERO H 2 O 2 V-Phase = 6 Log reduction The right solution to eliminate a wide spectrum of microorganisms quickly and effectively. The presence
More informationIndustry Perspective on PET Manufacturing Comparison of EU and US
Standards for Imaging Endpoints and Manufacturing of PET Radiopharmaceuticals Industry Perspective on PET Manufacturing Comparison of EU and US Guidances and associated Regulations Natcher Conference Center
More informationBFS IOA BFS Training 2018 Kunming Qualification and Validation of a BFS-Installation including CIP/SIP
Qualification and Validation of a BFS-Installation including CIP/SIP Presented by Christoph Bohn and Stefan Kiesel Director Rommelag Pharma Service Senior Manager Rommelag Pharma Service Coyright BFS IOA
More informationUNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL CLEANROOMS
DEPARTMENT OF VETERANS AFFAIRS Veterans Health Administration Washington DC 20420 IL 10-2006-008 In Reply Refer To: 10NB UNDER SECRETARY FOR HEALTH S INFORMATION LETTER MICROBIOLOGICAL ASSESSMENT OF PHARMACEUTICAL
More informationSingle-Use Final Fill: Benefits and Considerations
Single-Use Final Fill: Benefits and Considerations TENDÊNCIAS DE TECNOLOGIAS DE FABRICAÇÃO E ASSÉPTICA DE MEDICAMENTOS Ana Luísa Lampert Cadore Sales Specialist SU & Aseptic Process Solutions ana.cadore@merckgroup.com
More informationSeptember 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim
More informationAseptiSafe CONTAINED ASEPTIC TRANSFER VALVES. Handling sensitive ingredients and components in aseptic processing
AseptiSafe CONTAINED ASEPTIC TRANSFER VALVES Handling sensitive ingredients and components in aseptic processing Simple in process sterilization High containment performance for hazardous products www.thechargepoint.com
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationThe most effective bio-decontamination equipment. Innovative solutions for life sciences
The most effective bio-decontamination equipment Innovative solutions for life sciences WHY CHOOSE The control of microbiological contamination is necessary to ensure that production and research meet
More informationINTEGRATED VPHP DECONTAMINATION SYSTEMS THE EMERGING UTILITY
INTEGRATED VPHP DECONTAMINATION SYSTEMS THE EMERGING UTILITY John Klostermyer, Ph.D. ISPE Product Show Track 3 Session 3 September 26, 2018 AGENDA 1. BACKGROUND INFORMATION 2. BENEFITS 3. PROCESS 4. BEST
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationA Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime
A Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime James Tucker Global Scientific Affairs Manager Ecolab Life Science A Case Study for an Improved
More informationContainment Barrier Systems
Containment Barrier Systems As an international leader, focused on Quality, Telstar partners with clients to provide high value on a global basis through innovation, advanced technology, absolute reliability
More informationHISTORY AND MILESTONES
HISTORY AND MILESTONES HISTORY AND MILESTONES DOC S.r.l., Documentation Organization & Consultancy, was established in 1997 by MASCO group C.E.O. Eng. Alberto Borella and Eng. Paolo Curtò who became Managing
More informationThe DPTE System. The original Rapid Transfer Port
The DPTE System The original Rapid Transfer Port The benchmark for sterile transfer The first choice for risk-free production Manufacturing technologies are pushing productivity further with ever higher
More informationThis compilation of the complex
Manufacturing in a Global Marketplace Reference Matrices on Regulations for Classified (Environmentally Controlled) Areas Betty Seawell, William Miele, and Jean Huxsoll The complex world of international
More informationTrends in Sterile Manufacturing Technologies
Trends in Sterile Manufacturing Technologies ISPE Thailand Annual Meeting Charlotte Enghave Fruergaard 2013.07.18 Where we come from 1930s Danish Novo and Nordisk Gentofte (later Novo Nordisk) employed
More informationReview Validation of aseptic processes for pharmaceuticals
OPEM www.opem.org Oriental Pharmacy and Experimental Medicine 2010 10(4), 231-238 DOI 10.3742/OPEM.2010.10.4.231 Review Validation of aseptic processes for pharmaceuticals Lincy Joseph*, Mathew George
More informationWhitepaper HVAC Pre-filtration
Whitepaper HVAC Pre-filtration In Pharmaceutical Facilities I N D U S T R Y I N S I G H T S Norman A. Goldschmidt September 11, 2011 Principal, Engineering www.geieng.com I N D U S T R Y I N S I G H T
More information